Antibody and T-cell responses associated with experimental human malaria infection or vaccination show limited relationships

Immunology. 2015 May;145(1):71-81. doi: 10.1111/imm.12428.

Abstract

This study examined specific antibody and T-cell responses associated with experimental malaria infection or malaria vaccination, in malaria-naive human volunteers within phase I/IIa vaccine trials, with a view to investigating inter-relationships between these types of response. Malaria infection was via five bites of Plasmodium falciparum-infected mosquitoes, with individuals reaching patent infection by 11-12 days, having harboured four or five blood-stage cycles before drug clearance. Infection elicited a robust antibody response against merozoite surface protein-119 , correlating with parasite load. Classical class switching was seen from an early IgM to an IgG1-dominant response of increasing affinity. Malaria-specific T-cell responses were detected in the form of interferon-γ and interleukin-4 (IL-4) ELIspot, but their magnitude did not correlate with the magnitude of antibody or its avidity, or with parasite load. Different individuals who were immunized with a virosome vaccine comprising influenza antigens combined with P. falciparum antigens, demonstrated pre-existing interferon-γ, IL-2 and IL-5 ELIspot responses against the influenza antigens, and showed boosting of anti-influenza T-cell responses only for IL-5. The large IgG1-dominated anti-parasite responses showed limited correlation with T-cell responses for magnitude or avidity, both parameters being only negatively correlated for IL-5 secretion versus anti-apical membrane antigen-1 antibody titres. Overall, these findings suggest that cognate T-cell responses across a range of magnitudes contribute towards driving potentially effective antibody responses in infection-induced and vaccine-induced immunity against malaria, and their existence during immunization is beneficial, but magnitudes are mostly not inter-related.

Keywords: T cells; antibodies; infectious diseases; malaria.

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Protozoan / immunology*
  • Antibody Formation / drug effects*
  • Cytokines / immunology
  • Female
  • Humans
  • Immunity, Cellular / drug effects*
  • Immunoglobulin G / immunology
  • Immunoglobulin M / immunology
  • Malaria Vaccines / administration & dosage*
  • Malaria Vaccines / immunology
  • Malaria, Falciparum / immunology*
  • Malaria, Falciparum / pathology
  • Malaria, Falciparum / prevention & control
  • Male
  • Merozoite Surface Protein 1 / administration & dosage
  • Merozoite Surface Protein 1 / immunology
  • Middle Aged
  • Plasmodium falciparum / immunology*
  • T-Lymphocytes / immunology*

Substances

  • Antibodies, Protozoan
  • Cytokines
  • Immunoglobulin G
  • Immunoglobulin M
  • Malaria Vaccines
  • Merozoite Surface Protein 1